News

Tiny fatty (lipid) particles can be used to enhance the delivery of gene editing tools, such as CRISPR-Cas9, to targeted cells and considerably improve their ability to possibly treat human disorders like Huntington’s disease, researchers reported. Their study, “Fast and Efficient CRISPR/Cas9 Genome Editing In Vivo Enabled by…

Eligible Huntington’s disease patients would likely participate in a gene therapy trial regardless of the study design, but they are more inclined toward those with less invasive interventions and without a placebo group, a questionnaire-based study suggests. The results may be useful to design more patient-centered clinical trials assessing…

Changes in the shape of a brain region called the neostriatum — involved in motor and cognitive control — are associated with specific clinical features in people with Huntington’s disease at different stages of the disorder, a study has found. The results, “Striatal morphology and neurocognitive dysfunction…

Treatment with EIP Pharma’s investigational therapy neflamapimod (VX-745) can restore nerve cells’ communications and prevent their progressive degeneration and death, new preclinical results show. All together these data further support neflamapimod’s use to treat several neurodegenerative disorders characterized by impairment in nerve…